Celyad Oncology SA (NASDAQ:CYAD)

Delayed Data
As of Nov 24
 0.00 / 0.00%
Today’s Change
Today|||52-Week Range

Stock Price Forecast

The 4 analysts offering 12-month price forecasts for Celyad Oncology SA have a median target of 14.38, with a high estimate of 20.00 and a low estimate of 8.03. The median estimate represents a +290.83% increase from the last price of 3.68.

Analyst Recommendations

The current consensus among 5 polled investment analysts is to Buy stock in Celyad Oncology SA. This rating has held steady since November, when it was unchanged from a Buy rating.Move your mouse over past
months for detail


Earnings and Sales Forecasts

Current Quarter

Earnings per Share
Reporting Date

Earnings per Share

Move your mouse over a quarter or year to see how estimates have changed over time.

Growthquarterly --
Growthannually -20.88%


Growthquarterly -100.00%
Growthannually 136,882.76%
Key to the earnings and sales forecast charts.